These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 18606527

  • 1. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.
    Quaak SG, van den Berg JH, Toebes M, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B.
    Eur J Pharm Biopharm; 2008 Oct; 70(2):429-38. PubMed ID: 18606527
    [Abstract] [Full Text] [Related]

  • 2. Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.
    Quaak SG, Nuijen B, Haanen JB, Beijnen JH.
    J Pharm Biomed Anal; 2009 Feb 20; 49(2):282-8. PubMed ID: 19111423
    [Abstract] [Full Text] [Related]

  • 3. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.
    Przybylowski M, Bartido S, Borquez-Ojeda O, Sadelain M, Rivière I.
    Vaccine; 2007 Jun 28; 25(27):5013-24. PubMed ID: 17537555
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A.
    J Immunother; 2008 Jun 28; 31(2):215-23. PubMed ID: 18481391
    [Abstract] [Full Text] [Related]

  • 5. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
    Pavlenko M, Leder C, Pisa P.
    Expert Rev Vaccines; 2005 Jun 28; 4(3):315-27. PubMed ID: 16026247
    [Abstract] [Full Text] [Related]

  • 6. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
    Kazaks A, Balmaks R, Voronkova T, Ose V, Pumpens P.
    Biotechnol J; 2008 Nov 28; 3(11):1429-36. PubMed ID: 18956370
    [Abstract] [Full Text] [Related]

  • 7. Plasmid DNA- and messenger RNA-based anti-cancer vaccination.
    Weide B, Garbe C, Rammensee HG, Pascolo S.
    Immunol Lett; 2008 Jan 15; 115(1):33-42. PubMed ID: 18006079
    [Abstract] [Full Text] [Related]

  • 8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 15; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 9. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M, López-Vázquez AB, de Cerio AL, Huarte E, Casares N, Prieto J, Borrás-Cuesta F, Lasarte JJ, Sarobe P.
    Scand J Immunol; 2009 Feb 15; 69(2):80-9. PubMed ID: 19144076
    [Abstract] [Full Text] [Related]

  • 10. Long term stability of lyophilized plasmid DNA pDERMATT.
    van der Heijden I, Beijnen JH, Nuijen B.
    Int J Pharm; 2013 Sep 10; 453(2):648-50. PubMed ID: 23792100
    [Abstract] [Full Text] [Related]

  • 11. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
    Lee SW, Li H, Strong TV, Moore SE, Conry RM.
    J Immunother; 2000 Sep 10; 23(3):379-86. PubMed ID: 10838667
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 13. Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage.
    Cai Y, Rodriguez S, Rameswaran R, Draghia-Akli R, Juba RJ, Hebel H.
    Vaccine; 2010 Feb 23; 28(8):2046-52. PubMed ID: 19896448
    [Abstract] [Full Text] [Related]

  • 14. [General principles and first clinical trials of therapeutic vaccines against cancer].
    Baurain JF, Van der Bruggen P, Van den Eynde BJ, Coulie PG, Van Baren N.
    Bull Cancer; 2008 Mar 23; 95(3):327-35. PubMed ID: 18390413
    [Abstract] [Full Text] [Related]

  • 15. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
    Bråve A, Hallengärd D, Gudmundsdotter L, Stout R, Walters R, Wahren B, Hallermalm K.
    Vaccine; 2009 Jun 08; 27(28):3692-6. PubMed ID: 19428161
    [Abstract] [Full Text] [Related]

  • 16. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, Old L, Valmori D, Ayyoub M.
    J Immunother; 2009 Jun 08; 32(2):161-8. PubMed ID: 19238015
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
    Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM.
    J Immunother; 2005 Jun 08; 28(4):382-8. PubMed ID: 16000957
    [Abstract] [Full Text] [Related]

  • 18. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
    Barsoum AL, Liu B, Rohrer JW, Coggin JH, Tucker JA, Pannell LK, Schwarzenberger PO.
    Biomaterials; 2009 Jun 08; 30(17):3091-9. PubMed ID: 19268360
    [Abstract] [Full Text] [Related]

  • 19. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.
    Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S.
    J Immunother; 2008 Jun 08; 31(2):180-8. PubMed ID: 18481387
    [Abstract] [Full Text] [Related]

  • 20. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
    Balasse E, Gatouillat G, Patigny D, Andry MC, Madoulet C.
    Vaccine; 2009 Oct 19; 27(44):6107-9. PubMed ID: 19686694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.